Program:

12.00 – 13.00    Lunch  

13.00 – 13.10    Welcome by local organizers Aline Engbers (Merus) & Swantje Völler (Genmab)           

The role of modelling and simulation in supporting the discovery and development of multi-specific antibodies and/or antibody-drug conjugates

13.10 – 13.40    Alexander Kulesza (ESQlabs)

From molecular to systems’ level modeling of bispecific T-cell engagers

13.40 – 14.10    Suruchi Bakshi (Certara)

QSP modelling of multispecific T-cell engagers: Regulatory considerations and opportunities for synergy with pharmacometrics

14.10 – 14.30    Paul Lemarre (NovaInSilico)

Overcoming challenges in QSP modeling of bispecific antibodies: taking cell encounter in perspective

14.30 – 15.20    Coffee break    

15.20 – 15.40    Swantje Völler (Genmab)

Modelling strategies for antibody drug conjugates

15.40 – 16.00    Eline van Maanen (Certara)

A sequential population pharmacokinetic model of Zilovertamab vedotin in patients with hematologic malignancies extrapolated to the pediatric population

Pharmacometric research of early career scientists

16.00 – 16.15    Julia Stolk (Leiden University/Certara)

A Quantitative Systems Pharmacology Model to Investigate the Crucial Role of Epithelial Damage in the Pathogenesis of Inflammatory Bowel Disease

16.15 – 16.30    Aymara Sancho Araiz (Leiden University)

Population physiologically-based pharmacokinetic model to describe the hepatic and intestinal ontogeny of CYP3A4 in pediatric patients

16.30 – 16.45    Marije Otto (CHDR)

Characterization of oral esketamine’s first pass metabolism in healthy volunteers using a semi-physiologic modeling approach

16.45 – 17.00    Xuanlin Liu (Leiden University)

Viral dynamic modelling of nirmatrelvir against in vitro SARS-COV-2 infection with different treatment initiation times

17.00 – 18.00    Drinks